drugset
drugset / Trial / NCT02175056

A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study

NCT02175056 ↗

Phase 1 Completed 58 enrolled Handok Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The study design of this trial is a Dose-Block Randomized, Placebo controlled (Double-blind), Active Controlled(Open-label), Dose-escalation.

Timeline

Start
2014-05
Primary completion
2015-01
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Anakinra Protein / enzyme biologic 100 mg Subcutaneous
Subject HL2351 Unknown 1 mg/kg Subcutaneous
Subject HL2351 Unknown 2 mg/kg Subcutaneous
Subject HL2351 Unknown 4 mg/kg Subcutaneous
Subject HL2351 Unknown 8 mg/kg Subcutaneous
Subject HL2351 Unknown 12 mg/kg Subcutaneous

Indications

No indication recorded.